Snapshot from Jun 28, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Atezolizumab
Other

Atezolizumab

Tracked across 1 events · 6 articles · First seen Jun 11, 2026 · Last active Jun 11, 2026

Sentiment
70
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (1)
4 70
Regulatory
FDA accepts Roche Tecentriq sBLA
Roche>>> announced that the United States — Food and Drug Administration>>> has accepted its supplemental Biologics License Application (sBLA) for adjuvant Atezolizumab>>> and Atezolizumab Hybreza in combination with chemotherapy for stage III deficient DNA mismatch…
Impact: Atezolizumab>>> is the drug at the center of this event, with its sBLA accepted for Priority Review by the United States — Food and Drug Administration>>> for stage III colon cancer.
Jun 11, 2026 · 6 articles
NEWSDESK
Track Atezolizumab live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.